Insmed shares are trading higher after announcing that no agreement was reached between the company and AstraZeneca and Insmed retains full worldwide development and commercialization rights for brensocatib in all indications other than COPD or asthma development.
Portfolio Pulse from Benzinga Newsdesk
Insmed shares are trading higher after announcing that no agreement was reached between the company and AstraZeneca. Insmed retains full worldwide development and commercialization rights for brensocatib in all indications other than COPD or asthma development.
June 13, 2024 | 2:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Insmed shares are trading higher after the company announced it retains full worldwide development and commercialization rights for brensocatib in all indications other than COPD or asthma development, following no agreement with AstraZeneca.
The news that Insmed retains full worldwide rights for brensocatib, except for COPD or asthma development, is positive for the company as it maintains control over a potentially valuable asset. This has led to a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100